In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...
The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a ...
Eli Lilly (LLY) ended the recent trading session at $797.48, demonstrating a -0.3% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.16% ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...